Case Studies

Real-world evidence of delivering strategic insights to the pharmaceutical industry

Inpharmation runs global projects for the majority of top-50 pharmaceutical companies, across all major therapy areas.

Below you can browse a selection of projects showcasing examples of real-world strategic insights Inpharmation delivers.

To receive your full free copy of any case study:

Click on the business scenario that most interests you.
Submit a request via the download instructions.

Delivering gene therapy pricing strategy where payer interviews had failed: The power of Behavior-Based Pricing

Our client had a novel “one and done” gene therapy for an ultra-orphan disease. Despite previous payer research, the client lacked direction in which patient segments to target, what list to net pricing strategy to take, and what net price they could achieve. They needed an efficient and quantitative solution to inform their key development […]

Informing pricing prospects for a gene therapy in-licensing deal

To in-license, or not to in-license? Our client wanted to evaluate the price potential of a promising new product. The indication had a high unmet need and there was potential for the product to be used in future combination therapies. A lack of analogues and tight timelines added further complexity to the project. Inpharmation’s combination […]

Second indication, a second chance?

Analogue-based pricing had previously failed our client. They now had just eight weeks to make a launch or no-launch decision for a second indication. An evidence-based approach was needed to prevent repeating past mistakes.

Where do you start with pricing when the future landscape is unknown?

Limited clinical trial data, multiple lines of treatment and a changing pricing landscape presented challenges for the pricing assessment of an innovative oncology asset. However, Inpharmation’s evidence-based techniques were able to provide a flexible solution within the customer’s tight timelines.

How a flexible approach to pricing research allowed a rapid change of direction when unexpected trial results emerged

A pharma company wanted to launch its asset into a second indication. However, just as Inpharmation’s research was coming to an end, unexpected clinical trial results were revealed. This required a rapid change in strategy.

One chronic illness, many unlicensed treatments and one pipeline asset: Where do you start with pricing?

A leading pharma company needed to understand the price potential of their novel first-in class asset. Without any direct comparators, they were unsure what price they could achieve and how payers were going to behave. Inpharmation’s evidence-based approaches provided the perfect solution…

A clinical advance with a novel mechanism of action: What will its uptake look like?

With no obvious analogues and mixed messages from previous demand and qualitative research, our client was unsure what their novel asset’s uptake would look like. Inpharmation had the ideal approach to provide validated insights and evidence-based results…

How preconceived ideas of sample size nearly soured a great project

Pharma Specific Conjoint offered an ideal solution for our client. However, the significantly smaller sample size, compared to that of discrete-choice conjoint, lead to the project being met with reservations. A solution was needed to demonstrate the accuracy of our methodology.

How a lack of analogues could have undervalued a promising in-licensing opportunity

High unmet need offered a promising environment for a new asset; however, with no obvious analogues to quantify price potential, an approach ideal for an indication with no current treatments was needed…

A promising cardiovascular treatment in a highly prevalent disease

A highly prevalent disease with existing inexpensive therapies presented a challenging pricing environment for our client’s cardiovascular treatment. To deliver the optimal pricing strategy, Inpharmation used a combination of primary and secondary pricing techniques.

How analogue-based pricing confused a team of pricing experts

Traditional analogue-based pricing and qualitative payer interviews left our client confused when pricing an asset in a previously untreated disease with an uncertain patient population. Behavior-Based Pricing provided much needed clarity by drawing upon thousands of real-world payer decisions.